Almac Publish Second Validation of Stage II Colon Cancer Recurrence Assay in the Journal of Clinical Oncology

Press/Media: Research

Description

Almac Group’s Diagnostics business unit today announced the publication of the second validation study of their stage II colon cancer recurrence signature ColDx in the Journal of Clinical Oncology (JCO). The publication entitled ‘Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance)’ demonstrates that the ColDx assay is a significant, independent predictor of recurrence-free interval (RFI) in stage II colon cancer therefore indicating it’s potential utility with the traditional clinical markers of risk to refine patient prognosis

Period08 Aug 2016

Media contributions

1

Media contributions

  • TitleAlmac Publish Second Validation of Stage II Colon Cancer Recurrence Assay in the Journal of Clinical Oncology
    Degree of recognitionInternational
    Media name/outletJournal of Clinical Oncology
    Media typePrint
    CountryUnited Kingdom
    Date08/08/2016
    DescriptionAlmac Group’s Diagnostics business unit today announced the publication of the second validation study of their stage II colon cancer recurrence signature ColDx in the Journal of Clinical Oncology (JCO). The publication entitled ‘Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance)’ demonstrates that the ColDx assay is a significant, independent predictor of recurrence-free interval (RFI) in stage II colon cancer therefore indicating it’s potential utility with the traditional clinical markers of risk to refine patient prognosis
    URLascopubs.org/doi/abs/10.1200/JCO.2015.65.4699
    PersonsPaul Harkin